TARPLIN STRATEGIES LLC for GENENTECH, INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - taxes and fees assessed on the pharmaceutical industry.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Health Issues HCR
Public Law 111-148, the Patient Protection and Affordable Care Act - Medicare and Medicaid reimbursement for biotherapeutics, comparative effectiveness research, and legislative/regulatory issues involved in FDA approval of follow-on biologics. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Medicare and Medicaid reimbursement for biotherapeutics, payments under the 340B program, fees on pharmaceutical companies, the Medicare prescription drug benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Medicare/Medicaid MMM
Public Law 111-148, the Patient Protection and Affordable Care Act - Medicare and Medicaid reimbursement for biotherapeutics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Pharmacy PHA
H.R. 1548, the Pathway for Biosimilars Act, FDA approval of follow-on biologics. H.R. 1427 and S. 726, the Promoting Innovation and Access to Life-Saving Medicine Act, FDA approval of follow-on biologics. Public Law 111-148, the Patient Protection and Affordable Care Act - FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, design and structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Medicare and Medicaid reimbursement issues, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. S. 1232, the Pharmaceutical Market Access and Drug Safety Act, importation of prescription drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Medical/Disease Research/Clinical Labs MED
Public Law 111-148, the Patient Protection and Affordable Care Act of 2009 - authorization for comparative effectiveness research. S. 1213, the Patient-Centered Outcomes Research Act of 2009 - authorization for comparative effectiveness research.
| Lobbyist | Covered position, as disclosed |
|---|---|
| RICHARD JOSEPH TARPLIN | and Families |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.